Dr. Phillip H. Kuo discusses key findings from the VISION trial, which examined the impact of the radiopharmaceutical 177Lu-PSMA-617 on metastatic castration-resistant prostate cancer (mCRPC). The study found that for every unit increase in whole body tumor SUVmean, there was a 12% reduction in the risk of radiographic progression-free survival (rPFS) events and a 10% decrease in the risk of death. The trial demonstrated significant benefits in patient survival based on different quartiles of SUVmean, suggesting that better imaging could optimize treatment strategies. The FDA's involvement was pivotal, particularly in addressing regulatory concerns surrounding the unconventional approval of theranostics. Dr. Kuo emphasized the importance of combining imaging biomarkers with treatment to enhance patient outcomes. The article also mentions recent FDA updates regarding new imaging agents and their implications for prostate cancer treatment.
Tue, 08 Apr 2025 15:01:40 GMT | Urology Times